Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesCancer

PUBLISHER: Visiongain | PRODUCT CODE: 2037280

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2037280

Global mRNA Cancer Vaccine Market Report 2026-2036

PUBLISHED:
PAGES: 289 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5959.50
PDF (Team License - Up to 6 Users)
USD 7055.50
PDF (Site License)
USD 8288.50
PDF (Enterprise License - Includes Free Datasets)
USD 10473.65

Add to Cart

Description

Table of Contents

List of Tables

The global mRNA Cancer Vaccine market is projected to grow at a CAGR of 27.1% by 2036.

Visiongain has released its latest report, mRNA Cancer Vaccine Market Report 2026-2036, delivering a thorough examination of the global mRNA cancer vaccine market, covering market sizing, demand drivers, competitive dynamics, and revenue projections across core segments.

The global mRNA cancer vaccine market is expected to surpass US$1,200.0 million in 2026, with robust growth projected through to 2036, driven by the expanding role of precision oncology, breakthroughs in sequencing technologies, and a growing pipeline of clinical candidates.

This trajectory is supported by the ability of mRNA platforms to generate personalised, tumour-targeted immunotherapies based on individual genomic profiles, alongside continued innovation in neoantigen identification and advanced delivery systems.

Progress in genomic sequencing and neoantigen prediction algorithms is accelerating the development of next-generation personalised mRNA cancer vaccines. These platforms enable precise targeting of tumour-specific mutations, enhancing therapeutic effectiveness and supporting seamless integration into precision oncology treatment pathways.

Platform-level innovations - including self-amplifying mRNA constructs and improved lipid nanoparticle delivery systems - are enhancing scalability and compressing development timelines, cementing mRNA vaccines as a leading modality in next-generation oncology.

Trade Flows, Policy Shifts & Supply Chain Pressures

The mRNA cancer vaccine market is increasingly shaped by global trade conditions, evolving regulatory frameworks, and supply chain dependencies.

Production depends on specialised inputs - including lipid nanoparticles, nucleotides, and enzymes - sourced from global supply networks. Tariffs and trade restrictions have the potential to increase input costs and disrupt supply chains, with downstream effects on development timelines and commercial pricing.

Regulatory requirements and international collaboration also play a pivotal role in clinical development and route-to-market strategy, shaping access timelines and competitive positioning across key geographies.

Commercial Implications

  • Cost and pricing pressure: Rising input and manufacturing costs may weigh on therapy affordability
  • Supply chain shifts: Growing focus on regional manufacturing and sourcing resilience
  • Regulatory influence: Approval pathways and compliance obligations are shaping development timelines
  • Competitive positioning: Companies with scalable platforms and strong partnership networks are better placed

Company Intelligence

The mRNA cancer vaccine market features a blend of established biotechnology leaders and emerging innovators competing on platform capability, clinical progress, and the strength of their strategic alliances.

Key players including BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing their positions through clinical development, platform innovation, and targeted collaboration activity.

Competitive differentiation is increasingly driven by:

  • Technology and platform differentiation
  • Clinical pipeline strength
  • Manufacturing capability and scalability
  • Strategic partnerships and collaborations

This report examines how competitive positioning is shifting, pinpointing where value is being created and how strategies are expected to evolve across the forecast period.

Key Questions Answered

  • How is the mRNA cancer vaccine market evolving?
  • What is driving and restraining market growth?
  • Which segments and regions will generate the most revenue?
  • How will trade, policy, and supply chain dynamics impact the market?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global mRNA cancer vaccine market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across vaccine type, therapeutic approach, phase, indication, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Covers both quantitative forecasting and qualitative strategic analysis across technology, competition, policy, and supply chain dimensions.

Segmentation Framework

By Vaccine Type

  • Personalised
  • Semi-Personalised
  • Off-the-Shelf

By Therapeutic Approach

  • Monotherapy
  • Combination Therapy

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • High TMB Solid Tumors
  • GI Cancers
  • Gynecological Cancers
  • Breast Cancer
  • Other Solid Tumours

By End-user

  • Biopharma & Biotechnology Companies
  • Contract Development & Manufacturing Organisations (CDMOs)
  • Research Institutes & Academic Centres
  • Hospitals & Specialised Cancer Centres

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Acuitas
  • Arcturus Therapeutics
  • BioNTech
  • Cartesian Therapeutics Inc
  • Chimeron Bio
  • eTheRNA
  • Ethris GmbH
  • ImmuneSensor Therapeutics
  • Moderna
  • Orna Therapeutics
  • Replimune Group
  • Sana Biotechnology
  • ST Pharm
  • Strand Therapeutics

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The mRNA cancer vaccine market is moving quickly, propelled by precision medicine, platform innovation, and shifting global supply dynamics.
  • Organisations that understand these trends will be better placed to capture growth opportunities, manage risk, and strengthen their competitive positioning.
Show more
Product Code: PHA1384

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to mRNA Cancer Vaccine Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Late-Stage Clinical Validation Strengthening Commercial Confidence
      • 3.3.1.2 Dedicated Oncology Manufacturing and Automation Scale-Up
      • 3.3.1.3 Strategic Big Pharma Alliances and Capital Deployment
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Operational Complexity of Individualized Vaccine Workflows
      • 3.3.2.2 Regulatory and Reimbursement Uncertainty for Novel Oncology Platforms
      • 3.3.2.3 Competitive Landscape of Established and Emerging Immunotherapies
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expansion into Early-Stage and Adjuvant Cancer Settings
      • 3.3.3.2 Platform Replicability Across Multiple Tumor Types
      • 3.3.3.3 Strengthening mRNA Oncology Ecosystem and Infrastructure Investment
  • 3.4 U.S. Tariffs: What's the Impact on Global mRNA Cancer Vaccine Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Timeframe for Recovery
      • 3.4.3.4 Policy and Funding Support
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on mRNA Cancer Vaccine Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
    • 3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 mRNA Cancer Vaccine Market Analysis by Indication

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 4.4 High TMB Solid Tumors
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 GI Cancers
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Gynecological Cancers
    • 4.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Breast Cancers
    • 4.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Other Solid Tumors
    • 4.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Cancer Vaccine Market Analysis by Platform Type

  • 5.1 Key Findings
  • 5.2 Platform Type Segment: Market Attractiveness Index
  • 5.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 5.4 Personalized
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Off-the-Shelf
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Semi-Personalized
    • 5.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Cancer Vaccine Market Analysis by Therapeutic Approach

  • 6.1 Key Findings
  • 6.2 Therapeutic Approach Segment: Market Attractiveness Index
  • 6.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 6.4 Monotherapy
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Combination Therapy
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Cancer Vaccine Market Analysis by Phases

  • 7.1 Key Findings
  • 7.2 Phases Segment: Market Attractiveness Index
  • 7.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 7.4 Phase I
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Phase II
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Phase III
    • 7.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Phase IV
    • 7.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.7.2 Market Share by Region, 2029 & 2036 (%)

8 mRNA Cancer Vaccine Market Analysis by End-users

  • 8.1 Key Findings
  • 8.2 End Users Segment: Market Attractiveness Index
  • 8.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 8.4 Biopharma & Biotechnology Companies
    • 8.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Contract Development & Manufacturing Organizations (CDMOs)
    • 8.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Research Institutes & Academic Centers
    • 8.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Hospitals & Specialized Cancer Centers
    • 8.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)

9 mRNA Cancer Vaccine Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America mRNA Cancer Vaccine Market Analysis

  • 10.1 Key Findings
  • 10.2 North America mRNA Cancer Vaccine Market Attractiveness Index
  • 10.3 North America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 10.5 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 10.6 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 10.7 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 10.8 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 10.9 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 10.10 U.S. mRNA Cancer Vaccine Market Analysis
  • 10.11 Canada mRNA Cancer Vaccine Market Analysis

11 Europe mRNA Cancer Vaccine Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe mRNA Cancer Vaccine Market Attractiveness Index
  • 11.3 Europe mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 11.5 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 11.6 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 11.7 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 11.8 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 11.9 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 11.10 Germany mRNA Cancer Vaccine Market Analysis
  • 11.11 France mRNA Cancer Vaccine Market Analysis
  • 11.12 UK mRNA Cancer Vaccine Market Analysis
  • 11.13 Italy mRNA Cancer Vaccine Market Analysis
  • 11.14 Spain mRNA Cancer Vaccine Market Analysis
  • 11.15 Rest of Europe mRNA Cancer Vaccine Market Analysis

12 Asia Pacific mRNA Cancer Vaccine Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
  • 12.3 Asia Pacific mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 12.6 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 12.7 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 12.8 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 12.9 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 12.10 Japan mRNA Cancer Vaccine Market Analysis
  • 12.11 China mRNA Cancer Vaccine Market Analysis
  • 12.12 India mRNA Cancer Vaccine Market Analysis
  • 12.13 Australia mRNA Cancer Vaccine Market Analysis
  • 12.14 South Korea mRNA Cancer Vaccine Market Analysis
  • 12.15 Rest of Asia Pacific mRNA Cancer Vaccine Market Analysis

13 Latin America mRNA Cancer Vaccine Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America mRNA Cancer Vaccine Market Attractiveness Index
  • 13.3 Latin America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 13.5 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 13.6 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 13.7 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 13.8 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 13.9 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 13.10 Brazil mRNA Cancer Vaccine Market Analysis
  • 13.11 Mexico mRNA Cancer Vaccine Market Analysis
  • 13.12 Rest of Latin America mRNA Cancer Vaccine Market Analysis

14 MEA mRNA Cancer Vaccine Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA mRNA Cancer Vaccine Market Attractiveness Index
  • 14.3 MEA mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 14.5 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 14.6 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 14.7 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 14.8 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 14.9 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 14.10 GCC mRNA Cancer Vaccine Market Analysis
  • 14.11 South Africa mRNA Cancer Vaccine Market Analysis
  • 14.12 Rest of MEA mRNA Cancer Vaccine Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2026
  • 15.2 Strategic Outlook
  • 15.3 Moderna, Inc.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2021-2025
      • 15.3.3.2 R&D, 2021-2025
      • 15.3.3.3 Regional Market Shares, 2025
      • 15.3.3.4 Business Segment Market Shares, 2025
    • 15.3.4 Product Benchmarking
    • 15.3.5 SWOT Analysis
    • 15.3.6 Strategic Outlook
  • 15.4 BioNTech SE
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2021-2025
      • 15.4.3.2 R&D, 2021-2025
    • 15.4.4 Product Benchmarking
    • 15.4.5 SWOT Analysis
    • 15.4.6 Strategic Outlook
  • 15.5 Arcturus Therapeutics, Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2021-2025
      • 15.5.3.2 R&D, 2021-2025
      • 15.5.3.3 Business Segment Market Shares, 2025
    • 15.5.4 Product Benchmarking
    • 15.5.5 SWOT Analysis
    • 15.5.6 Strategic Outlook
  • 15.6 etherna
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Product Benchmarking
    • 15.6.4 SWOT Analysis
    • 15.6.5 Strategic Outlook
  • 15.7 ETHRIS
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Product Benchmarking
    • 15.7.4 Strategic Outlook
  • 15.8 ImmuneSensor Therapeutics
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Product Benchmarking
    • 15.8.4 Strategic Outlook
  • 15.9 Chimeron Bio
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Strategic Outlook
  • 15.10 Replimune Group Inc.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Product Benchmarking
  • 15.11 ST Pharm
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Product Benchmarking
    • 15.11.4 Strategic Outlook
  • 15.12 Sana Biotechnology
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Product Benchmarking
  • 15.13 Cartesian Therapeutics Inc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2021-2025
      • 15.13.3.2 R&D, 2021-2025
    • 15.13.4 Product Benchmarking
  • 15.14 Strand Therapeutics
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Product Benchmarking
    • 15.14.4 Strategic Outlook
  • 15.15 Acuitas
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Product Benchmarking
    • 15.15.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
Show more
Product Code: PHA1384

List of Tables

  • Table 1 mRNA Cancer Vaccine Market Snapshot, 2026 & 2036 (US$ Million, CAGR %)
  • Table 2 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 3 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: U- Shaped Recovery Scenario
  • Table 4 mRNA Cancer Vaccine Market Forecast by Region 2026-2036 (US$ Million, AGR%, CAGR%), Tariff Impact: L- Shaped Recovery Scenario
  • Table 5 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 6 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 7 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 8 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 9 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 10 Other Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 11 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 12 Personalized Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 13 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 14 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 15 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 16 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 17 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 18 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 19 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 20 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 21 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 22 Phase IV Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 23 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 24 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 25 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 26 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 27 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 28 mRNA Cancer Vaccine Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 29 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 30 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 31 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 32 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 33 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 34 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 35 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 36 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 37 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 38 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 39 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 40 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 41 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 42 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 43 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 44 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 45 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 46 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 47 Spain mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 48 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 49 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 50 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 51 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 52 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 53 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 54 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 55 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 56 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 57 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 58 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 59 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 60 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 61 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 62 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 63 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 64 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 65 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 66 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 67 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 68 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 69 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 70 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 71 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 72 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 73 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 74 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 75 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 76 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 77 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 78 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 79 Strategic Outlook
  • Table 80 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Moderna, Inc.: Product Benchmarking
  • Table 82 Moderna, Inc.: SWOT Analysis
  • Table 83 Moderna, Inc.: Strategic Outlook
  • Table 84 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 85 BioNTech SE: Product Benchmarking
  • Table 86 BioNtech SE: SWOT Analysis
  • Table 87 BioNTech SE: Strategic Outlook
  • Table 88 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 89 Arcturus Therapeutics, Inc.: Product Benchmarking
  • Table 90 Arcturus Therapeutics, Inc.: SWOT Analysis
  • Table 91 Arcturus Therapeutics, Inc. : Strategic Outlook
  • Table 92 etherna: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 93 etherna: Product Benchmarking
  • Table 94 etherna: SWOT Analysis
  • Table 95 etherna: Strategic Outlook
  • Table 96 ETHRIS: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 97 ETHRIS: Product Benchmarking
  • Table 98 ETHRIS: Strategic Outlook
  • Table 99 ImmuneSensor Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 100 ImmuneSensor Therapeutics: Product Benchmarking
  • Table 101 ImmuneSensor Therapeutics: Strategic Outlook
  • Table 102 Chimeron Bio: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 103 Chimeron Bio: Product Benchmarking
  • Table 104 Chimeron Bio: Strategic Outlook
  • Table 105 Replimune Group Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 106 Replimune Group Inc.: Product Benchmarking
  • Table 107 ST Pharm: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 108 ST Pharm: Product Benchmarking
  • Table 109 ST Pharm: Strategic Outlook
  • Table 110 Sana Biotechnology: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 111 Sana Biotechnology: Product Benchmarking
  • Table 112 Cartesian Therapeutics Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 113 Cartesian Therapeutics Inc.: Product Benchmarking
  • Table 114 Strand Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 115 Strand Therapeutics: Product Benchmarking
  • Table 116 Strand Therapeutics: Strategic Outlook
  • Table 117 Acuitas: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 118 Acuitas: Product Benchmarking
  • Table 119 Acuitas: Strategic Outlook

List of Figures

  • Figure 1 mRNA Cancer Vaccine Market Segmentation
  • Figure 2 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
  • Figure 3 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
  • Figure 4 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
  • Figure 5 mRNA Cancer Vaccine Market Attractiveness Index by Region
  • Figure 6 mRNA Cancer Vaccine Market: Market Dynamics
  • Figure 7 mRNA Cancer Vaccine Market: Impact Analysis
  • Figure 8 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 9 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 10 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 11 Short Term & Long Term Planning
  • Figure 12 Impact of U.S. and China Trade War
  • Figure 13 Most Impacted Countries
  • Figure 14 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • Figure 15 mRNA Cancer Vaccine Market: Porter's Five Forces Analysis
  • Figure 16 mRNA Cancer Vaccine Market: PEST Analysis
  • Figure 17 mRNA Cancer Vaccine Market by Indication: Market Attractiveness Index
  • Figure 18 mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 19 mRNA Cancer Vaccine Market Share Forecast by Indication, 2026, 2031, 2036 (%)
  • Figure 20 High TMB Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 21 High TMB Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 22 GI Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 23 GI Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 24 Gynecological Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 25 Gynecological Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 26 Breast Cancers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Breast Cancers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Other Solid Tumors Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 29 Other Solid Tumors Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 mRNA Cancer Vaccine Market by Platform Type: Market Attractiveness Index
  • Figure 31 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 32 mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026, 2031, 2036 (%)
  • Figure 33 mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 34 Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 35 Off-the-Shelf Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 36 Off-the-Shelf Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 37 Semi-Personalized Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 38 Semi-Personalized Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 mRNA Cancer Vaccine Market by Therapeutic Approach: Market Attractiveness Index
  • Figure 40 mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 41 mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026, 2031, 2036 (%)
  • Figure 42 Monotherapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 43 Monotherapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 44 Combination Therapy Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 45 Combination Therapy Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 46 mRNA Cancer Vaccine Market by Phases: Market Attractiveness Index
  • Figure 47 mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 48 mRNA Cancer Vaccine Market Share Forecast by Phases, 2026, 2031, 2036 (%)
  • Figure 49 Phase I Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 50 Phase I Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 51 Phase II Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 52 Phase II Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 53 Phase III Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 54 Phase III Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 55 Phase IV Segment Market Forecast by Region
  • Figure 56 Phase IV Segment Market Share Forecast by Region, 2029 & 2036 (%)
  • Figure 57 mRNA Cancer Vaccine Market by End Users: Market Attractiveness Index
  • Figure 58 mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 59 mRNA Cancer Vaccine Market Share Forecast by End Users, 2026, 2031, 2036 (%)
  • Figure 60 Biopharma & Biotechnology Companies Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Biopharma & Biotechnology Companies Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 62 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 63 Contract Development & Manufacturing Organizations (CDMOs) Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 64 Research Institutes & Academic Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 65 Research Institutes & Academic Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 66 Hospitals & Specialized Cancer Centers Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 67 Hospitals & Specialized Cancer Centers Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 68 mRNA Cancer Vaccine Market Forecast by Region 2026 and 2036 (Revenue, CAGR%)
  • Figure 69 mRNA Cancer Vaccine Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 70 mRNA Cancer Vaccine Market by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 71 North America mRNA Cancer Vaccine Market Attractiveness Index
  • Figure 72 North America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 73 North America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 74 North America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 75 North America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 76 North America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 77 North America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 78 North America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
  • Figure 79 North America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 80 North America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
  • Figure 81 North America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 82 North America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
  • Figure 83 North America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 84 North America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
  • Figure 85 U.S. mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 86 Canada mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 87 Europe mRNA Cancer Vaccine Market Attractiveness Index
  • Figure 88 Europe mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 89 Europe mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 90 Europe mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 91 Europe mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 92 Europe mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 93 Europe mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 94 Europe mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
  • Figure 95 Europe mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 96 Europe mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
  • Figure 97 Europe mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 98 Europe mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
  • Figure 99 Europe mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 100 Europe mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
  • Figure 101 Germany mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 102 France mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 103 UK mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 104 Italy mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 105 Spain mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 106 Rest of Europe mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 107 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
  • Figure 108 Asia Pacific mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 109 Asia Pacific mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 110 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 111 Asia Pacific mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 112 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 113 Asia Pacific mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 114 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
  • Figure 115 Asia Pacific mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 116 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
  • Figure 117 Asia Pacific mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 118 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
  • Figure 119 Asia Pacific mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 120 Asia Pacific mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
  • Figure 121 Japan mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 122 China mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 123 India mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 124 Australia mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 125 South Korea mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 126 Rest of Asia Pacific mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 127 Latin America mRNA Cancer Vaccine Market Attractiveness Index
  • Figure 128 Latin America mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 129 Latin America mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 130 Latin America mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 131 Latin America mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 132 Latin America mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 133 Latin America mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 134 Latin America mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
  • Figure 135 Latin America mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 136 Latin America mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
  • Figure 137 Latin America mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 138 Latin America mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
  • Figure 139 Latin America mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 140 Latin America mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
  • Figure 141 Brazil mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 142 Mexico mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 143 Rest of Latin America mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 144 MEA mRNA Cancer Vaccine Market Attractiveness Index
  • Figure 145 MEA mRNA Cancer Vaccine Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 146 MEA mRNA Cancer Vaccine Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 147 MEA mRNA Cancer Vaccine Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 148 MEA mRNA Cancer Vaccine Market Forecast by Indication, 2026-2036 (US$ Million, AGR %)
  • Figure 149 MEA mRNA Cancer Vaccine Market Share Forecast by Indication, 2026 & 2036 (%)
  • Figure 150 MEA mRNA Cancer Vaccine Market Forecast by Platform Type, 2026-2036 (US$ Million, AGR %)
  • Figure 151 MEA mRNA Cancer Vaccine Market Share Forecast by Platform Type, 2026 & 2036 (%)
  • Figure 152 MEA mRNA Cancer Vaccine Market Forecast by Therapeutic Approach, 2026-2036 (US$ Million, AGR %)
  • Figure 153 MEA mRNA Cancer Vaccine Market Share Forecast by Therapeutic Approach, 2026 & 2036 (%)
  • Figure 154 MEA mRNA Cancer Vaccine Market Forecast by Phases, 2026-2036 (US$ Million, AGR %)
  • Figure 155 MEA mRNA Cancer Vaccine Market Share Forecast by Phases, 2026 & 2036 (%)
  • Figure 156 MEA mRNA Cancer Vaccine Market Forecast by End Users, 2026-2036 (US$ Million, AGR %)
  • Figure 157 MEA mRNA Cancer Vaccine Market Share Forecast by End Users, 2026 & 2036 (%)
  • Figure 158 GCC mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 159 South Africa mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 160 Rest of MEA mRNA Cancer Vaccine Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 161 mRNA Cancer Vaccine Market: Company Share/Ranking, 2026
  • Figure 162 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Billion, AGR%)
  • Figure 163 Moderna, Inc.: R&D, 2021-2025 (US$ Billion, AGR%)
  • Figure 164 Moderna, Inc.: Regional Market Shares, 2025
  • Figure 165 Moderna, Inc.: Business Segment Market Shares, 2025
  • Figure 166 BioNTech SE: Net Revenue, 2021-2025 (US$ Billion, AGR%)
  • Figure 167 BioNTech SE: R&D, 2021-2025 (US$ Billion, AGR%)
  • Figure 168 Arcturus Therapeutics, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 169 Arcturus Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
  • Figure 170 Arcturus Therapeutics, Inc.: Business Segment Market Shares, 2025
  • Figure 171 Cartesian Therapeutics Inc.: Net Revenue, 2021-2025 (US$ Million, AGR%)
  • Figure 172 Cartesian Therapeutics, Inc.: R&D, 2021-2025 (US$ Million, AGR%)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!